EUCTR2005-003552-35-FR
Active, not recruiting
Phase 1
Clinical study to evaluate the efficacity and safety of octagam®10% in idiopathic thrombocytopenic purpura in adults - N/A
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Octapharma AG
- Enrollment
- 116
- Status
- Active, not recruiting
- Last Updated
- 4 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •\- Age of at least 18 years.
- •\- Diagnosis of ITP according to standard criteria i.e. isolated thrombocytopenia with an otherwise normal peripheral blood smear (bone marrow examination optional), and absence of other causes of thrombocytopenia.
- •\- Platelet count of 20\.000/µL or less with or without bleeding manifestations.
- •\- Freely given written informed consent from patient.
- •\- Women of reproductive age: negative result on a pregnancy test (HCG\-based assay) and will practice contraception using a method of proven reliabilty for the duration of the study.
- •women of reproductive age: negative result on apregnancy test (HCG\-based assay) and will practise contraception using a method of proven reliability for the duration of the study)
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1\.2 Adults (18\-64 years) yes
- •F.1\.2\.1 Number of subjects for this age range
Exclusion Criteria
- •Chronic refractory ITP patients, defined as those who fail to respond to standard treatment (oral corticosteroids and intravenous immunglobulin and anti\-D) or require unacceptably high doses of corticosteroids to maintain a safe platelet count.
- •\- Thrombocytopenia secondary to other diseases (such as AIDS) or drug\-related thrombocytopenia.
- •\- Administration of IGIV, anti\-D or other platelet enhancing drugs within 30 days before enrollment, except for long\-term corticosteroid therapy in patients with chronic ITP when the dose has been stable during the preceding 30 days and no dosage increase is planned within 7 days after treatment.
- •\- Experimental treatment (eg Rituximab) within 3 months before enrollment.
- •\- Prophylactic preoperative treatment for elective splenectomy.
- •\- Live viral vaccination within the last month before study entry.
- •\- Emergency operation.
- •\- Severe liver or kidney disease (ALAT 5x \> normal value, creatinine \> 120 µmol/L).
- •\- History of hypersensitivity to blood or plasma derived products, or any component of the product, such as maltose.
- •\- Known IgA deficiency and antibodies against IgA.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
A clinical study to evaluate the advanatges and safety of long term CurQfen consumption in dementia patientsHealth Condition 1: null- DementiaCTRI/2018/03/012410Akay Flavours and Aromatics Private Limited48
Not yet recruiting
Phase 2
A trial to check the effect of Capsule and syrup Shwasi in the management of Shwas Roga w.s.r. to Bronchial Asthma.Health Condition 1: null- Patients with Episodic Bronchial AsthmaCTRI/2018/01/011184Shree Dhanwantri Herbals Amritsar
Completed
Not Applicable
A clinical study to evaluate the efficacy and safety of docetaxel with ribavirin in patients with progressive prostate cancer who have previously recieved docetaxelJPRN-UMIN000012521Department of Urology, Keio University School of Medicine20
Completed
Phase 4
Evaluate the safety and efficacy of test product in improvement of skin .CTRI/2023/02/050063ZeusHygia Life sciences Pvt Ltd80
Not yet recruiting
Not Applicable
A clinical study to evaluate the efficacy and safety of MegaCarti® as a treatment for cartilage regeneration in patients with knee joint cartilage injury : Multicenter, microfracture control, randomization, superiority clinical trialInjury, poisoning and certain other consequences of external causesKCT0008226&C BIO64